Cargando…

A Review in Management of Testicular Cancer: Single Center Review

BACKGROUND: Testicular cancer is one of the few solid cancers that can be cured even when it is metastasized with overall survival rate of more than 90%. The aim of this study was to establish the age adjusted incidence of testicular cancer and to critically assess the management of testicular tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hameed, Ammar, White, Bob, Chinegwundoh, Frank, Thwaini, Ali, Pahuja, Ajay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649662/
https://www.ncbi.nlm.nih.gov/pubmed/29147233
http://dx.doi.org/10.4021/wjon258w
_version_ 1783272577041432576
author Hameed, Ammar
White, Bob
Chinegwundoh, Frank
Thwaini, Ali
Pahuja, Ajay
author_facet Hameed, Ammar
White, Bob
Chinegwundoh, Frank
Thwaini, Ali
Pahuja, Ajay
author_sort Hameed, Ammar
collection PubMed
description BACKGROUND: Testicular cancer is one of the few solid cancers that can be cured even when it is metastasized with overall survival rate of more than 90%. The aim of this study was to establish the age adjusted incidence of testicular cancer and to critically assess the management of testicular tumor. METHODS: This is a quantitative retrospective study utilizing a review of clinical notes for patients who underwent testicular orchidectomy. The number of cancer cases, types of pathology and cancer staging were examined. RESULTS: There is no substantial difference between the crude and the age-standardized incidence, moreover no difference from the reported crude incidence by the Scottish intercollegiate guidelines. We found 55.1% of seminoma, 14.28% of non-seminoma and 30.61% of combined (seminoma and non-seminoma), and stage I disease in 61.22% of cases, stage II in 36.73% of cases, and stage IV in 2.04% of cases. Most of the cancers were in the age group 20 - 50 with the majority (48.97%) in the age group 31 - 40. About 42.85% of cases were identified with high tumor markers; higher percentage of seminoma at stage II (40.74%). CONCLUSIONS: There is no substantial difference between the crude and the age-standardized incidence, moreover no difference from the reported crude incidence. Most of the cancers were in the age group 20 - 50 with the majority (48.97%) in the age group 31 - 40. Only 25% of seminomas had elevated tumor markers. Moreover, it is important to re-enforce strict adaptation to the IGCCCG prognostic factor-based classifications.
format Online
Article
Text
id pubmed-5649662
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-56496622017-11-16 A Review in Management of Testicular Cancer: Single Center Review Hameed, Ammar White, Bob Chinegwundoh, Frank Thwaini, Ali Pahuja, Ajay World J Oncol Original Article BACKGROUND: Testicular cancer is one of the few solid cancers that can be cured even when it is metastasized with overall survival rate of more than 90%. The aim of this study was to establish the age adjusted incidence of testicular cancer and to critically assess the management of testicular tumor. METHODS: This is a quantitative retrospective study utilizing a review of clinical notes for patients who underwent testicular orchidectomy. The number of cancer cases, types of pathology and cancer staging were examined. RESULTS: There is no substantial difference between the crude and the age-standardized incidence, moreover no difference from the reported crude incidence by the Scottish intercollegiate guidelines. We found 55.1% of seminoma, 14.28% of non-seminoma and 30.61% of combined (seminoma and non-seminoma), and stage I disease in 61.22% of cases, stage II in 36.73% of cases, and stage IV in 2.04% of cases. Most of the cancers were in the age group 20 - 50 with the majority (48.97%) in the age group 31 - 40. About 42.85% of cases were identified with high tumor markers; higher percentage of seminoma at stage II (40.74%). CONCLUSIONS: There is no substantial difference between the crude and the age-standardized incidence, moreover no difference from the reported crude incidence. Most of the cancers were in the age group 20 - 50 with the majority (48.97%) in the age group 31 - 40. Only 25% of seminomas had elevated tumor markers. Moreover, it is important to re-enforce strict adaptation to the IGCCCG prognostic factor-based classifications. Elmer Press 2011-06 2011-06-08 /pmc/articles/PMC5649662/ /pubmed/29147233 http://dx.doi.org/10.4021/wjon258w Text en Copyright 2011, Hameed et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hameed, Ammar
White, Bob
Chinegwundoh, Frank
Thwaini, Ali
Pahuja, Ajay
A Review in Management of Testicular Cancer: Single Center Review
title A Review in Management of Testicular Cancer: Single Center Review
title_full A Review in Management of Testicular Cancer: Single Center Review
title_fullStr A Review in Management of Testicular Cancer: Single Center Review
title_full_unstemmed A Review in Management of Testicular Cancer: Single Center Review
title_short A Review in Management of Testicular Cancer: Single Center Review
title_sort review in management of testicular cancer: single center review
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649662/
https://www.ncbi.nlm.nih.gov/pubmed/29147233
http://dx.doi.org/10.4021/wjon258w
work_keys_str_mv AT hameedammar areviewinmanagementoftesticularcancersinglecenterreview
AT whitebob areviewinmanagementoftesticularcancersinglecenterreview
AT chinegwundohfrank areviewinmanagementoftesticularcancersinglecenterreview
AT thwainiali areviewinmanagementoftesticularcancersinglecenterreview
AT pahujaajay areviewinmanagementoftesticularcancersinglecenterreview
AT hameedammar reviewinmanagementoftesticularcancersinglecenterreview
AT whitebob reviewinmanagementoftesticularcancersinglecenterreview
AT chinegwundohfrank reviewinmanagementoftesticularcancersinglecenterreview
AT thwainiali reviewinmanagementoftesticularcancersinglecenterreview
AT pahujaajay reviewinmanagementoftesticularcancersinglecenterreview